Dipyridamole

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Dipyridamole

Examples of brand names: Persantin [DE; historical example]

ATC code: B01AC07

Main use (for orientation): Platelet inhibition

Documented research summary

Experiments using dipyridamole as a comparator or probe do not establish a drug interaction with a cannabinoid. No clinical finding for the pair established.

Uncertainties and limitations

Do not present adenosine/bleeding/cardiovascular hypotheses as quantified combination risks.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Dipyridamole: adenosine uptake/PDE, glucuronidation and biliary excretion.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Dipyridamole single-ingredient tablets, US DailyMed dated 15 April 2026; indication/clinical pharmacology/pharmacokinetics and interactions read. Adenosine-uptake and PDE inhibition; hepatic glucuronidation, biliary excretion, high protein binding. Effects on adenosine/regadenoson and cholinesterase inhibitors reported; no dedicated pharmacokinetic interaction studies of the tablets in the label.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [RLABEL_D0012]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: Dipyridamol – DailyMed Produktkennzeichnung [RLABEL_D0012]

Source role [CA_P_36781825]: Scope distinction / context

Statement supported: Comparator/probe result screened, not direct dipyridamole combination evidence.

Source: In vivo phenotypic validation of adenosine receptor-dependent activity of non-adenosine drugs. [CA_P_36781825]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[RLABEL_D0012] Dipyridamol – DailyMed Produktkennzeichnung

Original source / bibliographic reference

Authors: Regulatory product information; respective marketing authorisation holder

Year: 2026

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_36781825] In vivo phenotypic validation of adenosine receptor-dependent activity of non-adenosine drugs.

Original source / bibliographic reference

Authors: Xiao C, Gavrilova O, Liu N, Lewicki SA, Reitman ML, Jacobson KA.

Year: 2023

Source type: Primary / secondary publication; design and use described in the individual review

DOI: 10.1007/s11302-023-09924-3

PMID: 36781825

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility